オピオイド誘発性便秘症のグローバル市場2021

• 英文タイトル：Global Opioid-Induced Constipation Sales Market Report 2021

• レポートコード：QAF27810
• 出版社/出版日：QYResearch / 2021年4月21日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、143ページ
• 納品方法：Eメール（即日納品）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥592,000 (USD4,000)	▷ お問い合わせ
Multi User	￥888,000 (USD6,000)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

本市場調査資料では、世界のオピオイド誘発性便秘症市場について種類別（臭化メチルナルトレキソン、ルビプロストン、ナロキセゴール、その他）、用途別（病院、薬局）、地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2016年～2027年までの市場規模と予測（販売量、売上、価格）、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。
・オピオイド誘発性便秘症市場の概要
・世界の主要地域別オピオイド誘発性便秘症市場規模2016-2027
・主要プレイヤーの競争状況・市場シェア
・世界のオピオイド誘発性便秘症市場規模2016-2021：種類別（臭化メチルナルトレキソン、ルビプロストン、ナロキセゴール、その他）
・世界のオピオイド誘発性便秘症市場予測2012-2027：種類別（臭化メチルナルトレキソン、ルビプロストン、ナロキセゴール、その他）
・世界のオピオイド誘発性便秘症市場規模2016-2021：用途別（病院、薬局）
・世界のオピオイド誘発性便秘症市場予測2012-2027：用途別（病院、薬局）
・オピオイド誘発性便秘症のアメリカ市場規模と予測2016-2021
・オピオイド誘発性便秘症のヨーロッパ市場規模と予測2016-2021
・オピオイド誘発性便秘症の中国市場規模と予測2016-2021
・オピオイド誘発性便秘症の日本市場規模と予測2016-2021
・オピオイド誘発性便秘症の東南アジア市場規模と予測2016-2021
・オピオイド誘発性便秘症のインド市場規模と予測2016-2021
・主要プレイヤーの企業情報：事業概要・売上・企業動向
（Takeda Pharmaceuticals、Bayer、Sanofi、Mallinckrodt、Salix (Bausch Health)、AstraZeneca、Progenics Pharmaceuticals、Purdue Pharm、Nektar Therapeutics、Daiichi Sankyo、Prestige、GSK、Shionogi）
・オピオイド誘発性便秘症の製造コスト分析
・販売チャネル、流通業者、顧客
・オピオイド誘発性便秘症の市場動向・機会・課題
・調査の結論

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
In the last several years, global market of Opioid-Induced Constipation developed smoothly, with an average growth rate of 3.85% from the forecast period 2019 to 2025.

Market Analysis and Insights: Global Opioid-Induced Constipation Market
The global Opioid-Induced Constipation market was valued at US$ 2696.9 in 2020 and will reach US$ 3532.3 million by the end of 2027, growing at a CAGR of 4.6% during 2022-2027.

Global Opioid-Induced Constipation Scope and Market Size
The global Opioid-Induced Constipation market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Opioid-Induced Constipation market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others

Segment by Application
Hospital
Pharmacy

The Opioid-Induced Constipation market is analysed and market size information is provided by regions (countries). Segment by Application, the Opioid-Induced Constipation market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi

レポート目次

1 Opioid-Induced Constipation Market Overview
1.1 Opioid-Induced Constipation Product Scope
1.2 Opioid-Induced Constipation Segment by Type
1.2.1 Global Opioid-Induced Constipation Sales by Type (2016 & 2021 & 2027)
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Opioid-Induced Constipation Segment by Application
1.3.1 Global Opioid-Induced Constipation Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Opioid-Induced Constipation Market Estimates and Forecasts (2016-2027)
1.4.1 Global Opioid-Induced Constipation Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Opioid-Induced Constipation Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Opioid-Induced Constipation Price Trends (2016-2027)

2 Opioid-Induced Constipation Estimates and Forecasts by Region
2.1 Global Opioid-Induced Constipation Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Opioid-Induced Constipation Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
2.2.2 Global Opioid-Induced Constipation Revenue Market Share by Region (2016-2021)
2.3 Global Opioid-Induced Constipation Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Opioid-Induced Constipation Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Opioid-Induced Constipation Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Opioid-Induced Constipation Estimates and Projections (2016-2027)
2.4.2 Europe Opioid-Induced Constipation Estimates and Projections (2016-2027)
2.4.3 China Opioid-Induced Constipation Estimates and Projections (2016-2027)
2.4.4 Japan Opioid-Induced Constipation Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Opioid-Induced Constipation Estimates and Projections (2016-2027)
2.4.6 India Opioid-Induced Constipation Estimates and Projections (2016-2027)
3 Global Opioid-Induced Constipation Competition Landscape by Players
3.1 Global Top Opioid-Induced Constipation Players by Sales (2016-2021)
3.2 Global Top Opioid-Induced Constipation Players by Revenue (2016-2021)
3.3 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2020)
3.4 Global Opioid-Induced Constipation Average Price by Company (2016-2021)
3.5 Manufacturers Opioid-Induced Constipation Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Opioid-Induced Constipation Market Size by Type
4.1 Global Opioid-Induced Constipation Historic Market Review by Type (2016-2021)
4.1.1 Global Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
4.1.2 Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2021)
4.1.3 Global Opioid-Induced Constipation Price by Type (2016-2021)
4.2 Global Opioid-Induced Constipation Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Opioid-Induced Constipation Sales Forecast by Type (2022-2027)
4.2.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2022-2027)
4.2.3 Global Opioid-Induced Constipation Price Forecast by Type (2022-2027)
5 Global Opioid-Induced Constipation Market Size by Application
5.1 Global Opioid-Induced Constipation Historic Market Review by Application (2016-2021)
5.1.1 Global Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
5.1.2 Global Opioid-Induced Constipation Revenue Market Share by Application (2016-2021)
5.1.3 Global Opioid-Induced Constipation Price by Application (2016-2021)
5.2 Global Opioid-Induced Constipation Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Opioid-Induced Constipation Sales Forecast by Application (2022-2027)
5.2.2 Global Opioid-Induced Constipation Revenue Forecast by Application (2022-2027)
5.2.3 Global Opioid-Induced Constipation Price Forecast by Application (2022-2027)

6 North America Opioid-Induced Constipation Market Facts & Figures
6.1 North America Opioid-Induced Constipation Sales by Company
6.1.1 North America Opioid-Induced Constipation Sales by Company (2016-2021)
6.1.2 North America Opioid-Induced Constipation Revenue by Company (2016-2021)
6.2 North America Opioid-Induced Constipation Sales Breakdown by Type
6.2.1 North America Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
6.2.2 North America Opioid-Induced Constipation Sales Breakdown by Type (2022-2027)
6.3 North America Opioid-Induced Constipation Sales Breakdown by Application
6.3.1 North America Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
6.3.2 North America Opioid-Induced Constipation Sales Breakdown by Application (2022-2027)

7 Europe Opioid-Induced Constipation Market Facts & Figures
7.1 Europe Opioid-Induced Constipation Sales by Company
7.1.1 Europe Opioid-Induced Constipation Sales by Company (2016-2021)
7.1.2 Europe Opioid-Induced Constipation Revenue by Company (2016-2021)
7.2 Europe Opioid-Induced Constipation Sales Breakdown by Type
7.2.1 Europe Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
7.2.2 Europe Opioid-Induced Constipation Sales Breakdown by Type (2022-2027)
7.3 Europe Opioid-Induced Constipation Sales Breakdown by Application
7.3.1 Europe 143 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 143 Sales Breakdown by Application (2022-2027)

8 China Opioid-Induced Constipation Market Facts & Figures
8.1 China Opioid-Induced Constipation Sales by Company
8.1.1 China Opioid-Induced Constipation Sales by Company (2016-2021)
8.1.2 China Opioid-Induced Constipation Revenue by Company (2016-2021)
8.2 China Opioid-Induced Constipation Sales Breakdown by Type
8.2.1 China Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
8.2.2 China Opioid-Induced Constipation Sales Breakdown by Type (2022-2027)
8.3 China Opioid-Induced Constipation Sales Breakdown by Application
8.3.1 China 314 Sales Breakdown by Application (2016-2021)
8.3.2 China 314 Sales Breakdown by Application (2022-2027)

9 Japan Opioid-Induced Constipation Market Facts & Figures
9.1 Japan Opioid-Induced Constipation Sales by Company
9.1.1 Japan Opioid-Induced Constipation Sales by Company (2016-2021)
9.1.2 Japan Opioid-Induced Constipation Revenue by Company (2016-2021)
9.2 Japan Opioid-Induced Constipation Sales Breakdown by Type
9.2.1 Japan Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
9.2.2 Japan Opioid-Induced Constipation Sales Breakdown by Type (2022-2027)
9.3 Japan Opioid-Induced Constipation Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Opioid-Induced Constipation Market Facts & Figures
10.1 Southeast Asia Opioid-Induced Constipation Sales by Company
10.1.1 Southeast Asia Opioid-Induced Constipation Sales by Company (2016-2021)
10.1.2 Southeast Asia Opioid-Induced Constipation Revenue by Company (2016-2021)
10.2 Southeast Asia Opioid-Induced Constipation Sales Breakdown by Type
10.2.1 Southeast Asia Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Opioid-Induced Constipation Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Opioid-Induced Constipation Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India Opioid-Induced Constipation Market Facts & Figures
11.1 India Opioid-Induced Constipation Sales by Company
11.1.1 India Opioid-Induced Constipation Sales by Company (2016-2021)
11.1.2 India Opioid-Induced Constipation Revenue by Company (2016-2021)
11.2 India Opioid-Induced Constipation Sales Breakdown by Type
11.2.1 India Opioid-Induced Constipation Sales Breakdown by Type (2016-2021)
11.2.2 India Opioid-Induced Constipation Sales Breakdown by Type (2022-2027)
11.3 India Opioid-Induced Constipation Sales Breakdown by Application
11.3.1 India Opioid-Induced Constipation Sales Breakdown by Application (2016-2021)
11.3.2 India Opioid-Induced Constipation Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Opioid-Induced Constipation Business
12.1 Takeda Pharmaceuticals
12.1.1 Takeda Pharmaceuticals Corporation Information
12.1.2 Takeda Pharmaceuticals Business Overview
12.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
12.1.5 Takeda Pharmaceuticals Recent Development
12.2 Bayer
12.2.1 Bayer Corporation Information
12.2.2 Bayer Business Overview
12.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Bayer Opioid-Induced Constipation Products Offered
12.2.5 Bayer Recent Development
12.3 Sanofi
12.3.1 Sanofi Corporation Information
12.3.2 Sanofi Business Overview
12.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Sanofi Opioid-Induced Constipation Products Offered
12.3.5 Sanofi Recent Development
12.4 Mallinckrodt
12.4.1 Mallinckrodt Corporation Information
12.4.2 Mallinckrodt Business Overview
12.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Mallinckrodt Opioid-Induced Constipation Products Offered
12.4.5 Mallinckrodt Recent Development
12.5 Salix (Bausch Health)
12.5.1 Salix (Bausch Health) Corporation Information
12.5.2 Salix (Bausch Health) Business Overview
12.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
12.5.5 Salix (Bausch Health) Recent Development
12.6 AstraZeneca
12.6.1 AstraZeneca Corporation Information
12.6.2 AstraZeneca Business Overview
12.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.6.4 AstraZeneca Opioid-Induced Constipation Products Offered
12.6.5 AstraZeneca Recent Development
12.7 Progenics Pharmaceuticals
12.7.1 Progenics Pharmaceuticals Corporation Information
12.7.2 Progenics Pharmaceuticals Business Overview
12.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
12.7.5 Progenics Pharmaceuticals Recent Development
12.8 Purdue Pharm
12.8.1 Purdue Pharm Corporation Information
12.8.2 Purdue Pharm Business Overview
12.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Purdue Pharm Opioid-Induced Constipation Products Offered
12.8.5 Purdue Pharm Recent Development
12.9 Nektar Therapeutics
12.9.1 Nektar Therapeutics Corporation Information
12.9.2 Nektar Therapeutics Business Overview
12.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Nektar Therapeutics Opioid-Induced Constipation Products Offered
12.9.5 Nektar Therapeutics Recent Development
12.10 Daiichi Sankyo
12.10.1 Daiichi Sankyo Corporation Information
12.10.2 Daiichi Sankyo Business Overview
12.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Daiichi Sankyo Opioid-Induced Constipation Products Offered
12.10.5 Daiichi Sankyo Recent Development
12.11 Prestige
12.11.1 Prestige Corporation Information
12.11.2 Prestige Business Overview
12.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Prestige Opioid-Induced Constipation Products Offered
12.11.5 Prestige Recent Development
12.12 GSK
12.12.1 GSK Corporation Information
12.12.2 GSK Business Overview
12.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.12.4 GSK Opioid-Induced Constipation Products Offered
12.12.5 GSK Recent Development
12.13 Shionogi
12.13.1 Shionogi Corporation Information
12.13.2 Shionogi Business Overview
12.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Shionogi Opioid-Induced Constipation Products Offered
12.13.5 Shionogi Recent Development

13 Opioid-Induced Constipation Manufacturing Cost Analysis
13.1 Opioid-Induced Constipation Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Opioid-Induced Constipation
13.4 Opioid-Induced Constipation Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Opioid-Induced Constipation Distributors List
14.3 Opioid-Induced Constipation Customers

15 Market Dynamics
15.1 Opioid-Induced Constipation Market Trends
15.2 Opioid-Induced Constipation Drivers
15.3 Opioid-Induced Constipation Market Challenges
15.4 Opioid-Induced Constipation Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables
Table 1. Global Opioid-Induced Constipation Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Opioid-Induced Constipation Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Opioid-Induced Constipation Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Opioid-Induced Constipation Sales (K Units) by Region (2016-2021)
Table 5. Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Table 6. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Opioid-Induced Constipation Revenue Share by Region (2016-2021)
Table 8. Global Opioid-Induced Constipation Sales (K Units) Forecast by Region (2022-2027)
Table 9. Global Opioid-Induced Constipation Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Opioid-Induced Constipation Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Opioid-Induced Constipation Revenue Share Forecast by Region (2022-2027)
Table 12. Global Opioid-Induced Constipation Sales (K Units) of Key Companies (2016-2021)
Table 13. Global Opioid-Induced Constipation Sales Share by Company (2016-2021)
Table 14. Global Opioid-Induced Constipation Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Opioid-Induced Constipation Revenue Share by Company (2016-2021)
Table 16. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Opioid-Induced Constipation as of 2020)
Table 17. Global Opioid-Induced Constipation Average Price (USD/Unit) of Key Company (2016-2021)
Table 18. Manufacturers Opioid-Induced Constipation Manufacturing Sites and Area Served
Table 19. Manufacturers Opioid-Induced Constipation Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Opioid-Induced Constipation Sales (K Units) by Type (2016-2021)
Table 22. Global Opioid-Induced Constipation Sales Share by Type (2016-2021)
Table 23. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2016-2021)
Table 25. Global Opioid-Induced Constipation Sales Share by Type (2022-2027)
Table 26. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Opioid-Induced Constipation Revenue Share by Type (2022-2027)
Table 28. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2022-2027)
Table 29. Global Opioid-Induced Constipation Sales (K Units) by Application (2016-2021)
Table 30. Global Opioid-Induced Constipation Sales Share by Application (2016-2021)
Table 31. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2016-2021)
Table 33. Global Opioid-Induced Constipation Sales (K Units) by Application (2022-2027)
Table 34. Global Opioid-Induced Constipation Sales Share by Application (2022-2027)
Table 35. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Opioid-Induced Constipation Revenue Share by Application (2022-2027)
Table 37. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2022-2027)
Table 38. North America Opioid-Induced Constipation Sales (K Units) by Company (2016-2021)
Table 39. North America Opioid-Induced Constipation Sales Market Share by Company (2016-2021)
Table 40. North America Opioid-Induced Constipation Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Opioid-Induced Constipation Revenue Market Share by Company (2016-2021)
Table 42. North America Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 43. North America Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 44. North America Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 45. North America Opioid-Induced Constipation Sales Market Share by Type (2022-2027)
Table 46. North America Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 47. North America Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 48. North America Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 49. North America Opioid-Induced Constipation Sales Market Share by Application (2022-2027)
Table 50. Europe Opioid-Induced Constipation Sales (K Units) by Company (2016-2021)
Table 51. Europe Opioid-Induced Constipation Sales Market Share by Company (2016-2021)
Table 52. Europe Opioid-Induced Constipation Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Opioid-Induced Constipation Revenue Market Share by Company (2016-2021)
Table 54. Europe Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 55. Europe Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 56. Europe Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 57. Europe Opioid-Induced Constipation Sales Market Share by Type (2022-2027)
Table 58. Europe Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 59. Europe Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 60. Europe Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 61. Europe Opioid-Induced Constipation Sales Market Share by Application (2022-2027)
Table 62. China Opioid-Induced Constipation Sales (K Units) by Company (2016-2021)
Table 63. China Opioid-Induced Constipation Sales Market Share by Company (2016-2021)
Table 64. China Opioid-Induced Constipation Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Opioid-Induced Constipation Revenue Market Share by Company (2016-2021)
Table 66. China Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 67. China Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 68. China Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 69. China Opioid-Induced Constipation Sales Market Share by Type (2022-2027)
Table 70. China Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 71. China Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 72. China Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 73. China Opioid-Induced Constipation Sales Market Share by Application (2022-2027)
Table 74. Japan Opioid-Induced Constipation Sales (K Units) by Company (2016-2021)
Table 75. Japan Opioid-Induced Constipation Sales Market Share by Company (2016-2021)
Table 76. Japan Opioid-Induced Constipation Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Opioid-Induced Constipation Revenue Market Share by Company (2016-2021)
Table 78. Japan Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 79. Japan Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 80. Japan Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 81. Japan Opioid-Induced Constipation Sales Market Share by Type (2022-2027)
Table 82. Japan Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 83. Japan Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 84. Japan Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 85. Japan Opioid-Induced Constipation Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Opioid-Induced Constipation Sales (K Units) by Company (2016-2021)
Table 87. Southeast Asia Opioid-Induced Constipation Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Opioid-Induced Constipation Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Opioid-Induced Constipation Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 91. Southeast Asia Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 93. Southeast Asia Opioid-Induced Constipation Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 95. Southeast Asia Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 97. Southeast Asia Opioid-Induced Constipation Sales Market Share by Application (2022-2027)
Table 98. India Opioid-Induced Constipation Sales (K Units) by Company (2016-2021)
Table 99. India Opioid-Induced Constipation Sales Market Share by Company (2016-2021)
Table 100. India Opioid-Induced Constipation Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Opioid-Induced Constipation Revenue Market Share by Company (2016-2021)
Table 102. India Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 103. India Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 104. India Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 105. India Opioid-Induced Constipation Sales Market Share by Type (2022-2027)
Table 106. India Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 107. India Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 108. India Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 109. India Opioid-Induced Constipation Sales Market Share by Application (2022-2027)
Table 110. Takeda Pharmaceuticals Corporation Information
Table 111. Takeda Pharmaceuticals Description and Business Overview
Table 112. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. Takeda Pharmaceuticals Opioid-Induced Constipation Product
Table 114. Takeda Pharmaceuticals Recent Development
Table 115. Bayer Corporation Information
Table 116. Bayer Description and Business Overview
Table 117. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. Bayer Opioid-Induced Constipation Product
Table 119. Bayer Recent Development
Table 120. Sanofi Corporation Information
Table 121. Sanofi Description and Business Overview
Table 122. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. Sanofi Opioid-Induced Constipation Product
Table 124. Sanofi Recent Development
Table 125. Mallinckrodt Corporation Information
Table 126. Mallinckrodt Description and Business Overview
Table 127. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 128. Mallinckrodt Opioid-Induced Constipation Product
Table 129. Mallinckrodt Recent Development
Table 130. Salix (Bausch Health) Corporation Information
Table 131. Salix (Bausch Health) Description and Business Overview
Table 132. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 133. Salix (Bausch Health) Opioid-Induced Constipation Product
Table 134. Salix (Bausch Health) Recent Development
Table 135. AstraZeneca Corporation Information
Table 136. AstraZeneca Description and Business Overview
Table 137. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 138. AstraZeneca Opioid-Induced Constipation Product
Table 139. AstraZeneca Recent Development
Table 140. Progenics Pharmaceuticals Corporation Information
Table 141. Progenics Pharmaceuticals Description and Business Overview
Table 142. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 143. Progenics Pharmaceuticals Opioid-Induced Constipation Product
Table 144. Progenics Pharmaceuticals Recent Development
Table 145. Purdue Pharm Corporation Information
Table 146. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 147. Purdue Pharm Description and Business Overview
Table 148. Purdue Pharm Opioid-Induced Constipation Product
Table 149. Purdue Pharm Recent Development
Table 150. Nektar Therapeutics Corporation Information
Table 151. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 152. Nektar Therapeutics Description and Business Overview
Table 153. Nektar Therapeutics Opioid-Induced Constipation Product
Table 154. Nektar Therapeutics Recent Development
Table 155. Daiichi Sankyo Corporation Information
Table 156. Daiichi Sankyo Description and Business Overview
Table 157. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 158. Daiichi Sankyo Opioid-Induced Constipation Product
Table 159. Daiichi Sankyo Recent Development
Table 160. Prestige Corporation Information
Table 161. Prestige Description and Business Overview
Table 162. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 163. Prestige Opioid-Induced Constipation Product
Table 164. Prestige Recent Development
Table 165. GSK Corporation Information
Table 166. GSK Description and Business Overview
Table 167. GSK Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 168. GSK Opioid-Induced Constipation Product
Table 169. GSK Recent Development
Table 170. Shionogi Corporation Information
Table 171. Shionogi Description and Business Overview
Table 172. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 173. Shionogi Opioid-Induced Constipation Product
Table 174. Shionogi Recent Development
Table 175. Production Base and Market Concentration Rate of Raw Material
Table 176. Key Suppliers of Raw Materials
Table 177. Opioid-Induced Constipation Distributors List
Table 178. Opioid-Induced Constipation Customers List
Table 179. Opioid-Induced Constipation Market Trends
Table 180. Opioid-Induced Constipation Market Drivers
Table 181. Opioid-Induced Constipation Market Challenges
Table 182. Opioid-Induced Constipation Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid-Induced Constipation Product Picture
Figure 2. Global Opioid-Induced Constipation Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Opioid-Induced Constipation Sales Market Share by Application in 2021 & 2027
Figure 6. Hospital Examples
Figure 7. Pharmacy Examples
Figure 8. Global Opioid-Induced Constipation Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 9. Global Opioid-Induced Constipation Sales Growth Rate (2016-2027) & (US$ Million)
Figure 10. Global Opioid-Induced Constipation Sales (K Units) Growth Rate (2016-2027)
Figure 11. Global Opioid-Induced Constipation Price Trends Growth Rate (2016-2027) (USD/Unit)
Figure 12. Global Opioid-Induced Constipation Revenue Market Share by Region: 2016 VS 2021
Figure 13. Global Opioid-Induced Constipation Revenue Market Share by Region: 2021 VS 2027
Figure 14. North America Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2016-2027)
Figure 15. North America Opioid-Induced Constipation Sales (K Units) Growth Rate (2016-2027)
Figure 16. Europe Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2016-2027)
Figure 17. Europe Opioid-Induced Constipation Sales (Million USD) Growth Rate (2016-2027)
Figure 18. China Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2016-2027)
Figure 19. China Opioid-Induced Constipation Sales (Million USD) and Growth Rate (2016-2027)
Figure 20. Japan Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2016-2027)
Figure 21. Japan Opioid-Induced Constipation Sales (Million USD) Growth Rate (2016-2027)
Figure 22. Southeast Asia Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2016-2027)
Figure 23. Southeast Asia Opioid-Induced Constipation Sales (Million USD) Growth Rate (2016-2027)
Figure 24. India Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2016-2027)
Figure 25. India Opioid-Induced Constipation Sales (Million USD) Growth Rate (2016-2027)
Figure 26. Global 5 Largest Opioid-Induced Constipation Players Market Share by Revenue in Opioid-Induced Constipation: 2016 & 2020
Figure 27. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 28. Global Opioid-Induced Constipation Revenue Share by Type (2016-2021)
Figure 29. Global Opioid-Induced Constipation Revenue Growth Rate by Type in 2016 & 2020
Figure 30. Global Opioid-Induced Constipation Revenue Share by Application (2016-2021)
Figure 31. Global Opioid-Induced Constipation Revenue Growth Rate by Application in 2016 & 2020
Figure 32. North America Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 33. North America Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 34. Europe Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 35. Europe Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 36. China Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 37. China Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 38. Japan Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 39. Japan Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 40. Southeast Asia Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 41. Southeast Asia Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 42. India Opioid-Induced Constipation Sales Market Share by Type in 2020
Figure 43. India Opioid-Induced Constipation Sales Market Share by Application in 2020
Figure 44. Key Raw Materials Price Trend
Figure 45. Manufacturing Cost Structure of Opioid-Induced Constipation
Figure 46. Manufacturing Process Analysis of Opioid-Induced Constipation
Figure 47. Opioid-Induced Constipation Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

以下、関連資料のご紹介

世界のオピオイド誘発性副作用治療市場規模・現状・予測（2021年-2027年）

Global Opioid Induced Side Effects Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5911 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、オピオイド誘発性副作用治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（リスペリドン、メチルフェニデート、セチリジン、その他）、用途別市場規模（薬物過剰摂取治療、疼痛治療、その他）、主要地域別市場規...

世界のオピオイド使用障害市場規模・現状・予測（2021年-2027年）

Global Opioid Use Disorder Market Size, Status and Forecast 2021-2027
QFJ1-4617 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、オピオイド使用障害の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ブプレノルフィン、メタドン、ナルトレキソン）、用途別市場規模（中等度疼痛治療、重度疼痛治療）、主要地域別市場規模（北米、アメリカ、欧州...

世界の慢性特発性便秘治療市場規模・現状・予測（2021年-2027年）

Global Chronic Idiopathic Constipation Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4009 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、慢性特発性便秘治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（血液検査、S状結腸鏡検査、結腸内視鏡検査、バルーン排出検査、肛門直腸内圧測定、結腸通過検査、排便検査、その他）、用途別市場規模（病院、...

世界のオピオイド薬市場規模・現状・予測（2021年-2027年）

Global Opioid Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5910 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、オピオイド薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ブプレノルフィン、フェンタニル、ヒドロコドン、モルヒネ、オキシコドン、トラマドール、その他）、用途別市場規模（麻酔、鎮痛、咳抑制、下痢抑制、...

世界のオピオイド離脱治療市場規模・現状・予測（2021年-2027年）

Global Opioid Withdrawal Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4618 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、オピオイド離脱治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗炎症薬、吐き気止め薬、鎮痛薬、その他）、用途別市場規模（病院薬局、小売薬局、オンラインストア）、主要地域別市場規模（北米、アメリカ、...

世界の非オピオイド疼痛治療市場規模・現状・予測（2021年-2027年）

Global Non-Opioid Pain Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5894 2021年6月 106Pages
QYResearch社発行の本調査レポートでは、非オピオイド疼痛治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医療大麻治療、カプサイシン由来治療、メントール含有治療、オメガ3脂肪酸含有治療、ボツリヌス毒素）、用途別市場規模（整形外科・筋骨格痛...

世界の化学療法誘発性血小板減少症治療薬市場規模・現状・予測（2021年-2027年）

Global Chemotherapy Induced Thrombocytopenia Drugs Market Size, Status and Forecast 2021-2027
QFJ1-3999 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、化学療法誘発性血小板減少症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、注射薬）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア...

世界の薬物誘発性聴器毒性治療市場規模・現状・予測（2021年-2027年）

Global Drug Induced Ototoxicity Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4158 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、薬物誘発性聴器毒性治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（代替療法、医薬品、補聴器、人工内耳、福祉機器（ALD））、用途別市場規模（蝸牛薬原因聴器毒性、前庭薬原因聴器毒性）、主要地域別市場...

化学療法誘発性悪心・嘔吐（CINV）治療薬のグローバル市場2021

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Market Report 2021
QAF27613 2021年4月21日 134Pages
本市場調査資料では、世界の化学療法誘発性悪心・嘔吐（CINV）治療薬市場について種類別（5-HT3阻害剤、NK1阻害剤、その他）、用途別（高催吐性化学療法、中等度催吐性化学療法、低催吐性化学療法、その他）、地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2...

世界のヘパリン起因性血小板減少症 (HIT) 治療市場規模・現状・予測（2021年-2027年）

Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4300 2021年6月 106Pages
QYResearch社発行の本調査レポートでは、ヘパリン起因性血小板減少症 (HIT) 治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（診断、治療）、用途別市場規模（病院、診断センター、専門医クリニック、病院薬局）、主要地域別市場規模（北米、ア...

世界のオピオイド誘発性副作用治療市場規模・現状・予測（2021年-2027年） Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body a…
世界のオピオイド使用障害市場規模・現状・予測（2021年-2027年） An opioid is a synthetic or natural agent that stimulates opioid receptors and produces opium-like effects. Opioid use disorder is a problematic pattern of opioid use that causes significant impairment or distress. Increase in opioid epidemic in the U.S. coupled with establishment of government poli…
世界のオピオイド離脱治療市場規模・現状・予測（2021年-2027年） In some cases, usage of opioids causes addiction, and opioid withdrawal syndrome is a life-threatening condition resulting from opioid dependence. These drugs can also cause severe health problems and sometimes even result in overdose and loss of life. Hence this opioid dependence requires treatment…
世界のオピオイド薬市場規模・現状・予測（2021年-2027年） Opioid Drugs can act on the pain central system in the human brain, brainstem and other tissues, thus exerting a strong downward pain suppression effect. Opioid Drugs can not only bind to peripheral nerve opioid receptors, but also to opioid receptors in the gelatinous (second layer) sensory neurons…
世界の非オピオイド疼痛治療市場規模・現状・予測（2021年-2027年） Non-Opioid Pain Treatment address acute and chronic pain and regulatory issues faced by healthcare professionals. With growing concerns about the addictive nature of opioid painkillers, more and more companies are working to develop effective but not addictive therapies. The interest and demand for …